Hosted by AD/PD™ on UNLOK · 🇺🇸 US · EN · 15 episodes
Established thought leaders with verified media credentials.
AD/PD™ is the leading international platform dedicated to exploring the latest breakthroughs and treatments in Alzheimer's, Parkinson’s, and related neurodegenerative diseases. The "AD/PD™ Session Spotlight" series is an AI-powered podcast that brings you key insights from the AD/PD™ Conference, with expert presentations and research discussions transformed into concise, easy-to-digest episodes.Join us as we uncover the latest innovations, explore groundbreaking research, and discuss the future of neurodegenerative disease treatments and therapies.
AD/PD™ on UNLOK hosts The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases, a science show with 15 episodes published.
In this episode, we spotlight Forum Discussion 08 from the AD/PD™ 2025 International Conference — “Drug Development & Biomarkers in Rare CNS Diseases (ALS, FTD) from Basics to Approval – How to Define Success.” The discu
Show notesIn this episode, we highlight Forum Discussion 07 from the AD/PD™ 2025 International Conference — “Challenges and Opportunities for Anti-Tau Therapies in Clinical Trials – How Can We Make Hopes Come True?” The session wa
Show notesIn this episode, we spotlight Forum Discussion 06 from the AD/PD™ 2025 International Conference — “Therapy for AD, PD & LBD: Novel Translational Models, New Receptor- and Neuroinflammation-Based Targets – How Close Are W
Show notesIn this episode, we spotlight Plenary Lecture 06 from the AD/PD™ 2025 International Conference — “Pivotal Points in Prevention Trials and the New Era of Precision Medicine for Alzheimer’s Disease and Related Disorders.”
Show notesIn this episode, we spotlight Forum Discussion 5 from the AD/PD™ 2025 International Conference — “Novel Approaches to Accelerate Development of Biomarkers, Imaging, and Therapy of Alpha-Synuclein, LRRK2, and GBA Patholog
Show notesIn this episode, we highlight Plenary Lecture 05 from the AD/PD™ 2025 International Conference — “Pathogenic Mechanisms of Familial AD and Emerging Therapeutic Developments.” Chaired by Prof. Manfred Windisch (Austria),
Show notesIn this episode, we unpack the key insights from Forum Discussion 04 at the AD/PD™ 2025 International Conference — “Translational Drug Development in AD (Phase I–III) and Relevance for Treatment and Disease Modification:
Show notesIn this episode, we feature Plenary Lecture 04 from the AD/PD™ 2025 International Conference — the Eric N. Birch Memorial Lecture, titled “Treatment of DLB and PDD: Status and New Developments.” Chaired by Dr. Sandra Moo
Show notesIn this episode, we spotlight Forum Discussion 03 from the AD/PD™ 2025 International Conference: “Improving the Therapeutic Potential of Immunotherapies in AD – Can Novel Strategies or Next Generation Drugs Halt or Furth
Show notesIn this episode, we explore Plenary Lecture 2 from the AD/PD™ 2025 International Conference: “GLP-1R Agonist Effects in Brain.” Moderated by Dr. Cynthia Lemere (USA) and Dr. Henrietta Nielsen (Sweden), this featured lect
Show notesIn this episode, we dive into one of the most forward-looking conversations from the AD/PD™ 2025 International Conference — Forum Discussion 2, "Integrating Blood-Based, CSF and Imaging Biomarkers With Digital Tools and
Show notesIn this episode of AD/PD™ Session Spotlight, we present Plenary Lecture 1 from AD/PD™ 2025, titled "The Alzheimer's Disease Drug Development Pipeline: Observations and Implications," delivered by Dr. Jeffrey Cummings (US
Show notesIn episode 2 of AD/PD™ Session Spotlight, we feature Plenary Lecture 3, the Don Price Memorial Lecture, titled "Plasma Biomarkers for Dementias in the Era of Disease-Modifying Therapies," presented by Prof. Charlotte Teu
Show notesIn this episode of AD/PD™ Session Spotlight, we delve into Forum Discussion 1, "Varying Regulatory Philosophies and AD Approval Priorities – USA, EU, Asia, and Other Parts of the World," a dynamic exchange exploring how
Show notesWelcome to AD/PD™ Session Spotlight, an official podcast series by AD/PD™. The podcast will discuss the latest cutting-edge science and real-world clinical impact in Alzheimer’s, Parkinson’s, and related neurodegenerativ
Show notesSponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases, visit https://adpd.kenes.com/ for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent science coverage.
The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases is hosted by AD/PD™ on UNLOK. The show is categorised under science (life) and has published 15 episodes.
The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases has published 15 episodes.
The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases regularly covers science, life. It sits in the science category, with a life focus.
The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases average 21 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 10 days ago.
